Grant of Interim Extension of the Term of U.S. Patent No. 5,407,914; SURFAXIN® (Lucinactant), 68166-68167 [2011-28499]
Download as PDF
68166
Federal Register / Vol. 76, No. 213 / Thursday, November 3, 2011 / Notices
Regardless of fishing region or
species, each sector must be adequately
represented, and the intent is to have a
group that, as a whole, reflects an
appropriate and equitable balance and
mix of interests given the
responsibilities of the HMS AP. Criteria
for membership include one or more of
the following: (1) Experience in the
HMS recreational fishing industry; (2)
experience in the HMS commercial
fishing industry; (3) experience in
fishery-related industries (e.g., marinas,
bait and tackle shops); (4) experience in
the scientific community working with
HMS; and/or (5) representation of a
private, non-governmental, regional,
national, or international organization
representing marine fisheries; or
environmental, governmental, or
academic interests dealing with HMS.
Five additional members on the HMS
AP include one member representing
each of the following Councils: New
England Fishery Management Council,
the Mid-Atlantic Fishery Management
Council, the South Atlantic Fishery
Management Council, the Gulf of
Mexico Fishery Management Council,
and the Caribbean Fishery Management
Council. The HMS AP also includes 22
ex-officio participants: 20
representatives of the coastal states and
two representatives of the interstate
commissions (the Atlantic States Marine
Fisheries Commission and the Gulf
States Marine Fisheries Commission).
NMFS will provide the necessary
administrative support, including
technical assistance, for the HMS AP.
However, NMFS will not compensate
participants with monetary support of
any kind. Depending on availability of
funds, members may be reimbursed for
travel costs related to the HMS AP
meetings.
C. Meeting Schedule
srobinson on DSK4SPTVN1PROD with NOTICES
Meetings of the HMS AP will be held
as frequently as necessary but are
routinely held twice each year in the
spring and fall. The meetings may be
held in conjunction with public
hearings.
Dated: October 31, 2011.
Steven Thur,
Acting Director, Office of Sustainable
Fisheries, National Marine Fisheries Service.
[FR Doc. 2011–28553 Filed 11–2–11; 8:45 am]
BILLING CODE 3510–22–P
VerDate Mar<15>2010
16:50 Nov 02, 2011
Jkt 226001
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No. PTO–C–2011–0054]
Discontinuing the Mass Mailing of
Paper Fee Schedules to Registered
Attorneys, Agents, and Deposit
Account Holders
United States Patent and
Trademark Office, Commerce.
ACTION: Notice.
AGENCY:
The United States Patent and
Trademark Office (USPTO) is
discontinuing the mass mailing of
revised paper fee schedules to registered
attorneys, agents, and deposit account
holders when fees are adjusted due to
enactment of legislation or fluctuations
in the Consumer Price Index. Since a
substantial majority of filings and fee
payments are submitted on-line, and the
most up-to-date fee schedule is always
available and maintained on-line, the
USPTO has discontinued the mass
mailing of the paper fee schedules. The
current fee schedule is essentially built
into the on-line systems (e.g., EFS–Web,
TEAS, accessible through the USPTO
home page, etc.), which display the
current fee amounts required at the time
of submitting the payment.
DATES: Effective Date: November 3,
2011.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Matthew Lee, Office of Finance,
Receipts Accounting Division, by
telephone at (571) 272–6343; or by mail
addressed to: Mail Stop 16, Director of
the USPTO, P.O. Box 1450, Alexandria,
VA 22313–1450.
SUPPLEMENTARY INFORMATION: The
USPTO is discontinuing the mass
mailing of revised paper fee schedules
that have been sent to registered
attorneys, agents, and deposit account
holders since the early 1990s. Since
1998, the revised paper fee schedules
have always indicated that the most upto-date fee amounts and information are
maintained on the USPTO Web site.
This availability of the fee amounts and
information renders paper fee schedules
obsolete.
The purpose of the mass mailings was
to provide the practitioners with
advance notice of upcoming fee
adjustments at a time when filings and
fee payments were mainly submitted by
mail. Due to the lead time needed for
finalizing, bulk printing, and mass
mailing of the paper fee schedules, the
paper fee schedules have sometimes
been mailed out weeks after the new
fees are already in effect. Currently over
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
90 percent of patent applications are
filed on-line via EFS–Web, and over 98
percent of trademark applications are
filed on-line via TEAS.
The official, current USPTO fee
schedule will continue to be available
and maintained on the USPTO Web site
at https://www.uspto.gov/about/offices/
cfo/finance/fees.jsp. Additionally, those
wishing to receive a paper copy of the
current USPTO fee schedule can obtain
this copy by calling the USPTO Contact
Center at (571) 272–1000 or (800) 786–
9199.
Dated: October 28, 2011.
Teresa Stanek Rea,
Deputy Under Secretary of Commerce for
Intellectual Property and Deputy Director of
the United States Patent and Trademark
Office.
[FR Doc. 2011–28536 Filed 11–2–11; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No. PTO–P–2011–0057]
Grant of Interim Extension of the Term
of U.S. Patent No. 5,407,914;
SURFAXIN® (Lucinactant)
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
The United States Patent and
Trademark Office has issued an Order
Granting Interim Extension for a third
one-year interim extension of the term
of U.S. Patent No. 5,407,914.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE,
P.O. Box 1450, Alexandria, VA 22313–
1450; by fax marked to her attention at
(571) 273–7755, or by email to
Mary.Till@uspto.gov.
SUMMARY:
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to one year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On September 19, 2011, Discovery
Laboratories Inc., on behalf of patent
SUPPLEMENTARY INFORMATION:
E:\FR\FM\03NON1.SGM
03NON1
Federal Register / Vol. 76, No. 213 / Thursday, November 3, 2011 / Notices
owner Scripps Research Institute, timely
filed an application under 35 U.S.C.
156(d)(5) for an additional interim
extension of the term of U.S. Patent No.
5,407,914. The patent claims the human
drug product, SURFAXIN®
(lucinactant), and a method of using
SURFAXIN® (lucinactant). The
application indicates that a New Drug
Application, NDA No. 21–746, for the
human drug product SURFAXIN®
(lucinactant) has been filed, and is
currently undergoing regulatory review
before the Food and Drug
Administration for permission to market
or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional one year
as required by 35 U.S.C. 156(d)(5)(B).
Because it is apparent that the
regulatory review period will continue
beyond the extended expiration date of
the patent, November 17, 2011, interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
5,407,914 is granted for a period of one
additional year from the extended
expiration date of the patent, i.e., until
November 17, 2012.
Dated: October 28, 2011.
Robert W. Bahr,
Acting Associate Commissioner for Patent
Examination Policy, United States Patent and
Trademark Office.
[FR Doc. 2011–28499 Filed 11–2–11; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
United States Patent and Trademark
Office
[Docket No. PTO–C–2011–0069]
National Medal of Technology and
Innovation Nomination Evaluation
Committee Meeting
United States Patent and
Trademark Office.
ACTION: Notice of closed meeting.
AGENCY:
The National Medal of
Technology and Innovation (NMTI)
Nomination Evaluation Committee will
meet in closed session on Friday,
November 18, 2011. The primary
purpose of the meeting is to discuss the
relative merits of persons, teams and
companies nominated for the 2011
NMTI Medal.
srobinson on DSK4SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
16:50 Nov 02, 2011
Jkt 226001
The meeting will convene
Friday, November 18, 2011, at
approximately 9 a.m., and adjourn at
approximately 5 p.m.
ADDRESSES: The meeting will be held at
the United States Patent and Trademark
Office, 600 Dulany Street, Alexandria,
VA 22314.
FOR FURTHER INFORMATION CONTACT:
Vikrum Aiyer, Program Manager,
National Medal of Technology and
Innovation Program, United States
Patent and Trademark Office, 600
Dulany Street, Alexandria, VA 22314;
telephone (571) 272–8818, or by
electronic mail: nmti@uspto.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to the Federal Advisory Committee Act,
5 U.S.C. app. 2, notice is hereby given
that the NMTI Nomination Evaluation
Committee, chartered to the United
States Department of Commerce, will
meet at the United States Patent and
Trademark Office campus in
Alexandria, Virginia.
The Secretary of Commerce is
responsible for recommending to the
President prospective NMTI Medal
recipients. The NMTI Nomination
Evaluation Committee evaluates the
nominations received pursuant to
public solicitation and makes its
recommendations for the Medal to the
Secretary. Committee members are
distinguished experts in the fields of
science, technology, business and patent
law drawn from both the public and
private sectors and are appointed by the
Secretary for three-year terms.
The NMTI Nomination Evaluation
Committee was established in
accordance with the Federal Advisory
Committee Act (FACA). The Committee
meeting will be closed to the public in
accordance with FACA and 5 U.S.C.
552b(c)(4), (6) and (9)(B), because the
discussion of the relative merit of the
Medal nominations is likely to disclose
information of a personal nature that
would constitute a clearly unwarranted
invasion of personal privacy; premature
disclosure of the Committee’s
recommendations would be likely to
significantly frustrate implementation of
the Medal Program; and the meeting
will include a Department of Commerce
Ethics Division presentation and
question and answer session which may
be closed to protect the privileged and
confidential personal financial
information of Committee members.
The Chief Financial Officer and
Assistant Secretary for Administration,
United States Department of Commerce,
formally determined on October 26,
2011, pursuant to Section 10(d) of the
Federal Advisory Committee Act, that
the meeting may be closed because
DATES:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
68167
Committee members are concerned with
matters that are within the purview of
5 U.S.C. 552b(c)(4), (6) and (9)(B). Due
to closure of this meeting, copies of any
minutes of the meeting will not be
available. A copy of the determination
is available for public inspection at the
United States Patent and Trademark
Office.
Dated: October 28, 2011.
Teresa Stanek Rea,
Deputy Under Secretary of Commerce for
Intellectual Property and Deputy Director of
the United States Patent and Trademark
Office.
[FR Doc. 2011–28500 Filed 11–2–11; 8:45 am]
BILLING CODE 3510–16–P
COMMODITY FUTURES TRADING
COMMISSION
Sunshine Act Meeting—Emergency
Meeting Notice
This notice that an emergency
meeting was held is published pursuant
to the provisions of the Government in
the Sunshine Act, Public Law 94–409,
5 U.S.C. 552b.
AGENCY HOLDING THE MEETING:
Commodity Futures Trading
Commission.
TIME AND DATE: The Commission held an
emergency closed meeting on October
31, 2011 at 12 p.m. The Commission, by
a recorded unanimous vote, determined
that the agency business required that
business of the agency required that the
meeting be held at that time.
PLACE: Three Lafayette Center, 1155
21st St. NW., Washington, DC, 9th Floor
Commission Conference Room.
STATUS: Closed.
MATTERS TO BE CONSIDERED: Registrant
Financial Matters.
CONTACT PERSON FOR MORE INFORMATION:
Sauntia S. Warfield, Assistant Secretary
of the Commission, 202–418–5084.
Sauntia S. Warfield,
Assistant Secretary of the Commission.
[FR Doc. 2011–28607 Filed 11–1–11; 11:15 am]
BILLING CODE 6351–01–P
CONSUMER PRODUCT SAFETY
COMMISSION
[CPSC Docket No. 12–C0003]
Spin Master, Inc. and Spin Master, Ltd.,
Provisional Acceptance of a
Settlement Agreement and Order
Consumer Product Safety
Commission.
ACTION: Notice.
AGENCY:
E:\FR\FM\03NON1.SGM
03NON1
Agencies
[Federal Register Volume 76, Number 213 (Thursday, November 3, 2011)]
[Notices]
[Pages 68166-68167]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-28499]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
[Docket No. PTO-P-2011-0057]
Grant of Interim Extension of the Term of U.S. Patent No.
5,407,914; SURFAXIN[supreg] (Lucinactant)
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
Order Granting Interim Extension for a third one-year interim extension
of the term of U.S. Patent No. 5,407,914.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Hatch-Waxman PTE, P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by email to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to one year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On September 19, 2011, Discovery Laboratories Inc., on behalf of
patent
[[Page 68167]]
owner Scripps Research Institute, timely filed an application under 35
U.S.C. 156(d)(5) for an additional interim extension of the term of
U.S. Patent No. 5,407,914. The patent claims the human drug product,
SURFAXIN[supreg] (lucinactant), and a method of using SURFAXIN[supreg]
(lucinactant). The application indicates that a New Drug Application,
NDA No. 21-746, for the human drug product SURFAXIN[supreg]
(lucinactant) has been filed, and is currently undergoing regulatory
review before the Food and Drug Administration for permission to market
or use the product commercially.
Review of the application indicates that, except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for an additional one year as
required by 35 U.S.C. 156(d)(5)(B). Because it is apparent that the
regulatory review period will continue beyond the extended expiration
date of the patent, November 17, 2011, interim extension of the patent
term under 35 U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 5,407,914 is granted for a period of one additional year
from the extended expiration date of the patent, i.e., until November
17, 2012.
Dated: October 28, 2011.
Robert W. Bahr,
Acting Associate Commissioner for Patent Examination Policy, United
States Patent and Trademark Office.
[FR Doc. 2011-28499 Filed 11-2-11; 8:45 am]
BILLING CODE 3510-16-P